Cargando…

Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission

BACKGROUND: The performance of blood biomarkers (mid-regional proadrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate) and clinical scores (Sequential Organ Failure Assessment (SOFA), National Early Warning Score (NEWS), and quick SOFA) was compared to identify pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez del Castillo, Juan, Wilson, Darius Cameron, Clemente-Callejo, Carlota, Román, Francisco, Bardés-Robles, Ignasi, Jiménez, Inmaculada, Orviz, Eva, Dastis-Arias, Macarena, Espinosa, Begoña, Tornero-Romero, Fernando, Giol-Amich, Jordi, González, Veronica, Llopis-Roca, Ferran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819475/
https://www.ncbi.nlm.nih.gov/pubmed/31665092
http://dx.doi.org/10.1186/s13054-019-2613-4
_version_ 1783463739156070400
author Gonzalez del Castillo, Juan
Wilson, Darius Cameron
Clemente-Callejo, Carlota
Román, Francisco
Bardés-Robles, Ignasi
Jiménez, Inmaculada
Orviz, Eva
Dastis-Arias, Macarena
Espinosa, Begoña
Tornero-Romero, Fernando
Giol-Amich, Jordi
González, Veronica
Llopis-Roca, Ferran
author_facet Gonzalez del Castillo, Juan
Wilson, Darius Cameron
Clemente-Callejo, Carlota
Román, Francisco
Bardés-Robles, Ignasi
Jiménez, Inmaculada
Orviz, Eva
Dastis-Arias, Macarena
Espinosa, Begoña
Tornero-Romero, Fernando
Giol-Amich, Jordi
González, Veronica
Llopis-Roca, Ferran
author_sort Gonzalez del Castillo, Juan
collection PubMed
description BACKGROUND: The performance of blood biomarkers (mid-regional proadrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate) and clinical scores (Sequential Organ Failure Assessment (SOFA), National Early Warning Score (NEWS), and quick SOFA) was compared to identify patient populations at risk of delayed treatment initiation and disease progression after presenting to the emergency department (ED) with a suspected infection. METHODS: A prospective observational study across three EDs. Biomarker and clinical score values were calculated upon presentation and 72 h, and logistic and Cox regression used to assess the strength of association. Primary outcomes comprised of 28-day mortality prediction and delayed antibiotic administration or intensive care (ICU) admission, whilst secondary outcomes identified subsequent disease progression. RESULTS: Six hundred eighty-four patients were enrolled with hospitalisation, ICU admission, and infection-related 28-day mortality rates of 72.8%, 3.4%, and 4.4%, respectively. MR-proADM and NEWS had the strongest association with hospitalisation and the requirement for antibiotic administration, whereas MR-proADM alone had the strongest association with ICU admission (OR [95% CI]: 5.8 [3.1 - 10.8]) and mortality (HR [95% CI]: 3.8 [2.2 - 6.5]). Patient subgroups with high MR-proADM concentrations (≥ 1.77 nmol/L) and low NEWS (< 5 points) values had significantly higher rates of ICU admission (8.1% vs 1.6%; p < 0.001), hospital readmission (18.9% vs. 5.9%; p < 0.001), infection-related mortality (13.5% vs. 0.2%; p < 0.001), and disease progression (29.7% vs. 4.9%; p < 0.001) than corresponding patients with low MR-proADM concentrations. ICU admission was delayed by 1.5 [0.25 – 5.0] days in patients with high MR-proADM and low NEWS values compared to corresponding patients with high NEWS values, despite similar 28-day mortality rates (13.5% vs. 16.5%). Antibiotics were withheld in 17.4% of patients with high MR-proADM and low NEWS values, with higher subsequent rates of ICU admission (27.3% vs. 4.8%) and infection-related hospital readmission (54.5% vs. 14.3%) compared to those administered antibiotics during ED treatment. CONCLUSIONS: Patients with low severity signs of infection but high MR-proADM concentrations had an increased likelihood of subsequent disease progression, delayed antibiotic administration or ICU admission. Appropriate triage decisions and the rapid use of antibiotics in patients with high MR-proADM concentrations may constitute initial steps in escalating or intensifying early treatment strategies.
format Online
Article
Text
id pubmed-6819475
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68194752019-10-31 Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission Gonzalez del Castillo, Juan Wilson, Darius Cameron Clemente-Callejo, Carlota Román, Francisco Bardés-Robles, Ignasi Jiménez, Inmaculada Orviz, Eva Dastis-Arias, Macarena Espinosa, Begoña Tornero-Romero, Fernando Giol-Amich, Jordi González, Veronica Llopis-Roca, Ferran Crit Care Research BACKGROUND: The performance of blood biomarkers (mid-regional proadrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate) and clinical scores (Sequential Organ Failure Assessment (SOFA), National Early Warning Score (NEWS), and quick SOFA) was compared to identify patient populations at risk of delayed treatment initiation and disease progression after presenting to the emergency department (ED) with a suspected infection. METHODS: A prospective observational study across three EDs. Biomarker and clinical score values were calculated upon presentation and 72 h, and logistic and Cox regression used to assess the strength of association. Primary outcomes comprised of 28-day mortality prediction and delayed antibiotic administration or intensive care (ICU) admission, whilst secondary outcomes identified subsequent disease progression. RESULTS: Six hundred eighty-four patients were enrolled with hospitalisation, ICU admission, and infection-related 28-day mortality rates of 72.8%, 3.4%, and 4.4%, respectively. MR-proADM and NEWS had the strongest association with hospitalisation and the requirement for antibiotic administration, whereas MR-proADM alone had the strongest association with ICU admission (OR [95% CI]: 5.8 [3.1 - 10.8]) and mortality (HR [95% CI]: 3.8 [2.2 - 6.5]). Patient subgroups with high MR-proADM concentrations (≥ 1.77 nmol/L) and low NEWS (< 5 points) values had significantly higher rates of ICU admission (8.1% vs 1.6%; p < 0.001), hospital readmission (18.9% vs. 5.9%; p < 0.001), infection-related mortality (13.5% vs. 0.2%; p < 0.001), and disease progression (29.7% vs. 4.9%; p < 0.001) than corresponding patients with low MR-proADM concentrations. ICU admission was delayed by 1.5 [0.25 – 5.0] days in patients with high MR-proADM and low NEWS values compared to corresponding patients with high NEWS values, despite similar 28-day mortality rates (13.5% vs. 16.5%). Antibiotics were withheld in 17.4% of patients with high MR-proADM and low NEWS values, with higher subsequent rates of ICU admission (27.3% vs. 4.8%) and infection-related hospital readmission (54.5% vs. 14.3%) compared to those administered antibiotics during ED treatment. CONCLUSIONS: Patients with low severity signs of infection but high MR-proADM concentrations had an increased likelihood of subsequent disease progression, delayed antibiotic administration or ICU admission. Appropriate triage decisions and the rapid use of antibiotics in patients with high MR-proADM concentrations may constitute initial steps in escalating or intensifying early treatment strategies. BioMed Central 2019-10-29 /pmc/articles/PMC6819475/ /pubmed/31665092 http://dx.doi.org/10.1186/s13054-019-2613-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gonzalez del Castillo, Juan
Wilson, Darius Cameron
Clemente-Callejo, Carlota
Román, Francisco
Bardés-Robles, Ignasi
Jiménez, Inmaculada
Orviz, Eva
Dastis-Arias, Macarena
Espinosa, Begoña
Tornero-Romero, Fernando
Giol-Amich, Jordi
González, Veronica
Llopis-Roca, Ferran
Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title_full Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title_fullStr Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title_full_unstemmed Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title_short Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
title_sort biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819475/
https://www.ncbi.nlm.nih.gov/pubmed/31665092
http://dx.doi.org/10.1186/s13054-019-2613-4
work_keys_str_mv AT gonzalezdelcastillojuan biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT wilsondariuscameron biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT clementecallejocarlota biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT romanfrancisco biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT bardesroblesignasi biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT jimenezinmaculada biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT orvizeva biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT dastisariasmacarena biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT espinosabegona biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT torneroromerofernando biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT giolamichjordi biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT gonzalezveronica biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT llopisrocaferran biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission
AT biomarkersandclinicalscorestoidentifypatientpopulationsatriskofdelayedantibioticadministrationorintensivecareadmission